GlassScriptPhysician profile
Jamie Michael Pelzel
NPI 1750340485
$36,232.80
in general payments reported to CMS, 2019-2025
24 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,840 · 2020: $4,670 · 2021: $6,360 · 2022: $11K · 2023: $7,263 · 2024: $215 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,875 · Food and Beverage: $1,082 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,875.00 |
| Food and Beverage | $1,081.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $880.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19,857.71 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,205.00 | 2021-2023 | Jardiance |
| Lilly USA, LLC | $3,337.50 | 2021-2022 | |
| Abiomed | $138.15 | 2022-2025 | |
| Nuwellis, INC. | $94.69 | 2023 | Aquadex Smartflow Console |
| Ancora Heart, INC. | $84.50 | 2024-2025 | Accucinch |
| Endotronix, INC. | $72.60 | 2021 | |
| Boston Scientific Corporation | $71.51 | 2019-2023 | |
| Cvrx, INC. | $44.09 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $39.60 | 2022-2025 | Camzyos |
| Heartflow, INC. | $36.83 | 2023-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $36.18 | 2021-2022 | |
| Scpharmaceuticals INC. | $30.23 | 2025 | |
| Amgen INC. | $27.95 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $22.48 | 2024 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $20.83 | 2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $20.26 | 2025 | |
| Cardiac Dimensions, INC. | $18.75 | 2023 | |
| Novo Nordisk INC | $18.56 | 2025 | Wegovy |
| United Therapeutics Corporation | $16.58 | 2023 | Tyvaso |
| Alnylam Pharmaceuticals INC. | $14.95 | 2024 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Pfizer INC. | $11.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Pelzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.